<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">Other demographic groups also are disproportionately affected by hepatitis C, evident by a higher prevalence among those groups. For example, in the USA, the overall hepatitis C antibody prevalence is estimated to be 1.6 %; however, it is 3 % among persons born during 1945–1965 [
 <xref ref-type="bibr" rid="CR13">13</xref>]; 5 % among military veterans [
 <xref ref-type="bibr" rid="CR26">26</xref>, 
 <xref ref-type="bibr" rid="CR27">27</xref>]; 6 % among blacks aged 30–49 years [
 <xref ref-type="bibr" rid="CR28">28</xref>]; 14 % among HIV-infected persons [
 <xref ref-type="bibr" rid="CR1">1</xref>]; and 23–39 % among the incarcerated [
 <xref ref-type="bibr" rid="CR26">26</xref>]. Additionally, some hepatitis C epidemics are fueled by contaminated injection equipment used in mass treatment campaigns, such as schistosomiasis treatment in Egypt during 1960–1980; HCV transmission is still ongoing today [
 <xref ref-type="bibr" rid="CR29">29</xref>].
</p>
